IP Library › Granted Patent US 7,736,638
Granted Patent B2
US 7,736,638 · App. 11/662,844 · Granted Jun 15, 2010

Interleukin-15 antagonist peptide

Assignee: Centro de Ingenieria Genetica y Biotecnologia
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,736,638
App. No.
11/662,844
Granted
Jun 15, 2010
Kind
B2
Abstract

Current invention is related to the molecular pharmacology branch particularly to a peptide belonging to the Interleukin-15 sequence (IL-15) which is able to inhibit IL-15 biological activity, analogues or mimetic of such peptides. In the current invention it is shown that the peptide inhibits both IL-15-induced T cells proliferation upon binding to the IL15 receptor a subunit (IL15Rα) and TNFα-mediated apoptosis. Besides, this invention is related to the use of this peptide in the treatment of several pathologies where aberrant IL-15 or IL-15Rα expression is associated to the disease progression.

Claims (9)

1. An isolated IL-15 activity antagonist peptide consisting of the amino acid sequence set forth in SEQ ID NO: 1.

2. The peptide according to claim 1 , wherein the peptide binds to an IL-15Rα cellular subunit or its soluble fraction.

3. The peptide according to claim 1 , wherein the peptide inhibits IL-15-dependent T cell proliferation activity.

4. The peptide according to claim 1 , being obtained by genetic manipulation or by chemical synthesis.

5. An isolated nucleic acid encoding the peptide of claim 1 , wherein the peptide is capable of binding cellular IL-15Rα or its soluble fraction and inhibiting IL-15-dependent T cell proliferation activity.

6. An expression vector comprising a nucleic acid encoding the peptide of claim 1 , wherein said peptide is capable of inhibiting IL-15-dependent T cell proliferation activity.

7. A method of treating rheumatoid arthritis in a mammal, comprising administering an effective amount of an isolated IL-15 activity antagonist peptide consisting of the amino acid sequence set forth in SEQ ID NO: 1 to the mammal.

8. A method of treating psoriasis in a mammal, comprising administering an effective amount of an isolated IL-15 activity antagonist peptide consisting of the amino acid sequence set forth in SEQ ID NO:1 to the mammal.

9. An immunogenic composition comprising a peptide according to claim 1 which inhibits IL-15-dependent T cell proliferation activity.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 30, 2008
From: SANTOS SAVIO, ALICIA; CABRALES RICO, ANIA; REYES ACOSTA, OSVALDO; GERONIMO PEREZ, HAYDEE; ARRIETA AGUERO, CELIA AURORA; PEREA RODRIGUEZ, SILVIO ERNESTO
To: CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA
Reel/Frame 021605/0496 →
Priority Claims (1)
CU 2004-0198 · Sep 17, 2004 · national
Continuity (1)
Related Publication 20090136511A1 · May 28, 2009